Sinclair Issues Statement on Merger Proposal with The E.W. Scripps Company
Get Alerts SBGI Hot Sheet
Join SI Premium – FREE
BALTIMORE--(BUSINESS WIRE)-- Sinclair, Inc. (Nasdaq: SBGI) (the “Company” or “Sinclair”) today made the following statement in response to The E.W. Scripps Company’s (Nasdaq: SSP) (“Scripps”) rejection of the Company’s proposal for a potential combination with Scripps:
“We are disappointed that despite Scripps encouraging Sinclair to make a proposal, Scripps’ board rejected the proposal without engaging. Our proposal was based on previous discussions and was responsive to concerns about Scripps’ communities, employees and shareholders. It delivers significant strategic and financial benefits for both companies and all shareholders and represents a substantial premium over both Scripps’ unaffected and current share price. We call on Scripps to engage with us regarding our proposal. We believe Scripps’ shareholders deserve a full and fair evaluation of this opportunity.”
About Sinclair:
Sinclair, Inc. is a diversified media company and a leading provider of local news and sports. The Company owns, operates and/or provides services to 179 television stations in 81 markets affiliated with all major broadcast networks; and owns Tennis Channel, the premium destination for tennis enthusiasts, and multicast networks CHARGE, Comet, ROAR and The Nest. Sinclair’s AMP Media produces a growing portfolio of digital content and original podcasts. Additional information about Sinclair can be found at www.sbgi.net.
Category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20251217606700/en/
Investor Contact:
Christopher C. King, VP, Investor Relations
(410) 568-1500
Media Contact:
Jessica Bellucci
[email protected]
Source: Sinclair, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology
- Lantern Expands Its Platform for Solving the Data Trust Problem with Strategic Acquisition and Key Executive Hires
- Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share